US006713481B1

(12) **United States Patent**
Andrews et al.

(10) **Patent No.:** US 6,713,481 B1
(45) **Date of Patent:** Mar. 30, 2004

(54) **CRYSTALLINE ANTIFUNGAL POLYMORPH**

(76) Inventors: **David R. Andrews**, 449 Baldwin Rd., Maplewood, NJ (US) 07040; **William Leong**, 705 Carleton Rd., Westfield, NJ (US) 07090; **Anantha Sudhakar**, 18 Snowden Rd., East Brunswick, NJ (US) 08816

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 721 days.

(21) Appl. No.: 09/166,445

(22) Filed: **Oct. 5, 1998**

Related U.S. Application Data

(60) Provisional application No. 60/061,231, filed on Oct. 17, 1997.

(51) Int. Cl.^{7} A61K 31/496; C07D 405/14
(52) U.S. Cl. 514/254.07; 544/366
(58) Field of Search 544/366; 514/252, 514/254.07

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,625,064 A	* 4/1997	Andrews et al.	544/366
5,661,151 A	* 8/1997	Saksena et al.	514/252
5,693,626 A	* 12/1997	Saksena et al.	514/85
5,703,079 A	* 12/1997	Saksena et al.	514/252
5,710,154 A	* 1/1998	Saksena et al.	514/252
5,714,490 A	* 2/1998	Saksena et al.	514/252

FOREIGN PATENT DOCUMENTS

WO	95/17407	* 6/1995	
WO	WO 96/33178	10/1996	
WO	96/38443	* 12/1996	

OTHER PUBLICATIONS

Munzel, Von K., *Progress in Drug Research*, 1996, vol. 10, pp. 227–230, Birkhauser, Basel, Switzerland.

* cited by examiner

Primary Examiner—Emily Bernhardt
(74) Attorney, Agent, or Firm—Thomas D. Hoffman

(57) **ABSTRACT**

The crystalline polymorph Form I of (–)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl] phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I

pharmaceutical compositions containing such a polymorph and methods of using such a polymorph to treat fungal infections in mammals are disclosed.

5 Claims, 10 Drawing Sheets